- Home
- TNXP vs HYLN Comparison
TNXP vs HYLN Comparison
Compare TNXP & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- HYLN
- Stock Information
- Founded
- TNXP 2007
- HYLN 2018
- Country
- TNXP United States
- HYLN United States
- Employees
- TNXP N/A
- HYLN N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- HYLN Construction/Ag Equipment/Trucks
- Sector
- TNXP Health Care
- HYLN Consumer Discretionary
- Exchange
- TNXP Nasdaq
- HYLN Nasdaq
- Market Cap
- TNXP 335.6M
- HYLN 279.7M
- IPO Year
- TNXP N/A
- HYLN N/A
- Fundamental
- Price
- TNXP $51.35
- HYLN $1.64
- Analyst Decision
- TNXP Buy
- HYLN Hold
- Analyst Count
- TNXP 1
- HYLN 1
- Target Price
- TNXP $70.00
- HYLN $2.00
- AVG Volume (30 Days)
- TNXP 1.8M
- HYLN 954.1K
- Earning Date
- TNXP 08-11-2025
- HYLN 08-12-2025
- Dividend Yield
- TNXP N/A
- HYLN N/A
- EPS Growth
- TNXP N/A
- HYLN N/A
- EPS
- TNXP N/A
- HYLN N/A
- Revenue
- TNXP $9,831,000.00
- HYLN $3,513,000.00
- Revenue This Year
- TNXP $22.87
- HYLN $575.94
- Revenue Next Year
- TNXP $711.66
- HYLN $255.00
- P/E Ratio
- TNXP N/A
- HYLN N/A
- Revenue Growth
- TNXP N/A
- HYLN 3559.38
- 52 Week Low
- TNXP $6.76
- HYLN $1.11
- 52 Week High
- TNXP $130.00
- HYLN $4.10
- Technical
- Relative Strength Index (RSI)
- TNXP 55.76
- HYLN 55.12
- Support Level
- TNXP $42.12
- HYLN $1.47
- Resistance Level
- TNXP $69.97
- HYLN $1.69
- Average True Range (ATR)
- TNXP 6.06
- HYLN 0.10
- MACD
- TNXP 1.01
- HYLN 0.01
- Stochastic Oscillator
- TNXP 45.73
- HYLN 77.42
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.